Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Testosterone intranasal - Acerus Pharmaceuticals Corporation

Next Previous
Drug Profile

Testosterone intranasal - Acerus Pharmaceuticals Corporation

Alternative Names: CompleoTRT™; MPP 10; Nasobol; NATESTO; TBS-1

Latest Information Update: 28 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mattern Pharmaceuticals
  • Developer Acerus Pharmaceuticals; Aytu BioPharma; Hyundai Pharmaceutical; Medac
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists; Growth stimulants; Testosterone congener stimulants; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypogonadism

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for phase-I development in Hypogonadism(In adolescents) in United Kingdom (Intranasal, Gel)
  • 15 Sep 2022 Launched for Hypogonadism in Canada (Intranasal)
  • 14 Jan 2022 Acerus Pharmaceuticals entered into a marketing agreement with Verity Pharmaceuticals for the exclusive rights to promote NATESTO in Puerto Rico

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top